Lack of high-dose radiation mediated prostate cancer promotion and low-dose radiation adaptive response in the TRAMP mouse model

Radiation Research

Volumn 180, Issue 4, 2013, Pages 376-388

  Lawrence, M D ^a   Ormsby, R J ^a   Blyth, B J ^a   Bezak, E ^b   England, G ^c   Newman, M R ^a   Tilley, W D ^d   Sykes, P J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c SA Pathology   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; DNA DAMAGE; EFFECT SIZE; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE WEIGHT; RADIATION DOSE; TRANSGENIC ANIMAL; TUMOR PROMOTION; WHOLE BODY RADIATION; X RAY;

ADENOCARCINOMA; ANIMALS; ANTIGENS, VIRAL, TUMOR; CARCINOGENESIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HISTONES; KI-67 ANTIGEN; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; WHOLE-BODY IRRADIATION;

EID: 84886574234     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR3381.2     Document Type: Article

References (74)

1. Grönberg H. Prostate cancer epidemiology. The Lancet 2003; 361(9360): 859-64.
2. Kuettel MR, Thraves PJ, Jung M, Varghese SP, Prasad SC, Rhim JS, et al. Radiation-induced Neoplastic Transformation of Human Prostate Epithelial Cells Cancer Res. 1996; 56(1): 5-10.
3. Hirose F, Takizawa S, Watanabe H, Terada Y, Fujii I. Induction of prostate carcinoma in rats by local X-irradiation. Nagasaki Igaku 1978; 53: 216-22. (Japanese)
4. Hirose F, Takizawa S, WatanabeH, Takeichi N. Development of adenocarcinoma of the prostate in ICR mice locally irradiated with X-rays. Japanese J Cancer Res (Gann) 1976; 67(3): 407-11.
5. Takizawa S, Hirose F. Role of testosterone in the development of radiation-induced prostate carcinoma in rats. Japanese J Cancer Res (Gann)1978; 69(5): 723-6.
6. Brown CE, Warren S. Carcinoma of the prostate in irradiated parabiotic rats. Cancer Res. 1978; 38(1): 159-62.
7. Norris WP, Fritz TE, Rehfeld CE, Poole CM. The response of the beagle dog to cobalt-60 gamma radiation: determination of the LD50(30) and description of associated changes. Radiat Res 1968; 35(3): 681-708.
8. Mittal A, Haley B, Paunesku D, Paunesku T, Woloschak G. Radiation-induced prostate cancer in large cohort of chronically irradiated beagle dogs. Int J Radiat Oncol Biol Phys 2009; 75(3): S533-S4.
9. Travis LB, Curtis RE, Fraumeni JF, Boice JD, Storm H, Andersson M, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997; 89(19): 1429-39.
10. Myles P, Evans S, Lophatananon A, Dimitropoulou P, Easton D, Key T, et al. Diagnostic radiation procedures and risk of prostate cancer. Br J Cancer 2008; 98(11): 1852-6.
11. Tapio S, Jacob V. Radioadaptive response revisited. Radiat Environ Biophys 2007; 46(1): 1-12.
12. Mitchel RE. Low doses of radiation reduce risk in vivo. Dose Response 2007; 5(1): 1-10.
13. Bauer G. Low dose radiation and intercellular induction of apoptosis: potential implications for the control of oncogenesis. Int J Radiat Biol 2007; 11(12): 873-88.
14. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci 1995; 92(8): 3439-43.
15. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 2004; 64(6): 2270-305.
16. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Diseases 1999; 2(2): 70-5.
17. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci 2001; 98(18): 10350-5.
18. Saleem M, Adhami VM, Ahmad N, Gupta S, Mukhtar H. Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res 2005; 11(1): 147-53.
19. McCarthy S, Caporali A, Enkemann S, Scaltriti M, Eschrich S, Davalli P, et al. Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol 2007; 1(2): 196-204.
20. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009; 15(6): 1947-53.
21. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 2005; 135(5): 989-95.
22. Mentor-Marcel R, Lamartiniere CA, Eltoum I-E, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001; 61(18): 6777-82.
23. El Touny LH, Banerjee PP. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009; 69(8): 3695-703.
24. El Touny LH, Banerjee PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis. 2007; 28(8): 1710-7.
25. Wechter WJ, Leipold DD, Murray ED, Jr., Quiggle D, McCracken JD, Barrios RS, et al. E-7869 (R-Flurbiprofen) Inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000; 60(8): 2203-8.
26. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64(9): 3334-43.
27. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal antiinflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10(22): 7727-37.
28. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, et al. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci 2005; 102(7): 2525-30.
29. Wikström P, Bylund A, Zhang JX, Hallmans G, Stattin P, Bergh A. Rye bran diet increases epithelial cell apoptosis and decreases epithelial cell volume in TRAMP (transgenic adenocarcinoma of the mouse prostate) tumors. Nutr Cancer 2005; 53(1): 111-6.
30. Raina K, Blouin M-J, Singh RP, Majeed N, Deep G, Varghese L, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007; 67(22): 11083-91.
31. Wadsworth TL, Worstell TR, Greenberg NM, Roselli CE. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP). The Prostate 2007; 67(6): 661-73.
32. Barve A, Khor T, Hao X, Keum Y-S, Yang C, Reddy B, et al. Murine prostate cancer inhibition by dietary phytochemicals - curcumin and phenyethylisothiocyanate. Pharm Res 2008; 25(9): 2181-9.
33. Khor TO, Yu S, Barve A, Hao X, Hong J-L, Lin W, et al. Dietary Feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2009; 69(17): 7096-102.
34. Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis 2011; 33(3): 644-51.
35. Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter melon extract impairs prostate cancer cell cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res 2011; 4(12): 2122-30.
36. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. The Prostate. 2008; 68(12): 1319-29.
37. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP Mouse as a model for prostate cancer. current protocols in immunology: John Wiley & Sons, Inc.; 2001.
38. Aukett RJ. The IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potential (0.035 mm Al-4 mm Cu HVL; 10-300 kV generating potential). Phys Med Biol 1999; 41(12): 2605.
39. Aukett RJ. Addendum to the IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potential (0.035 mm Al-4 mm Cu HVL). Phys Med Biol 2005; 50(12): 2739.
40. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A Grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 2003; 31(1): 31-8.
41. Lawrence M, Blyth B, Ormsby R, Tilley W, Sykes P. Falsepositive TUNEL staining observed in SV40 based transgenic murine prostate cancer models. Transgenic Res in press.
42. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biology. 2006; 7(10):R100.
43. Portess DI, Bauer G, Hill MA, O'Neill P. Low-Dose Irradiation of Nontransformed Cells Stimulates the Selective Removal of Precancerous Cells via Intercellular Induction of Apoptosis. Cancer Res. 2007; 67(3): 1246-53.
44. Feinendegen LE, Pollycove M, Neumann RD. Whole-body responses to low-level radiation exposure: New concepts in mammalian radiobiology. Exp Hematol 2007; 35(4, Suppl 1): 37-46.
45. Shellabarger CJ, Bond VP, Cronkite EP. Studies on radiationinduced mammary gland neoplasia in the rat: iv. The response of females to a single dose of sublethal total-body gamma radiation as studied until the first appearance of breast neoplasia or death of the animals. Radiat Res 1960; 13(2): 242-9.
46. Shellabarger CJ, Schmidt RW. Mammary neoplasia in the rat as related to dose of partial-body irradiation. Radiat Res 1967; 30(3): 497-506.
47. Storer JB, Mitchell TJ, Fry RJM. Extrapolation of the relative risk of radiogenic neoplasms across mouse strains and to man. Radiat Res 1988; 114(2): 331-53.
48. Mitchel RE, Jackson JS, McCann RA, Boreham DR. The adaptive response modifies latency for radiation-induced myeloid leukemia in CBA/H mice. Radiat Res 1999; 152(3): 273-9.
49. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and Effects of Ionizing Radiation. Volume II. Annex F - DNA Repair and Mutagenesis. Report to the General Assembly. UNSCEAR, 2000.
50. Goodhead D. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol. 1994; 65(1): 7-17.
51. Ponnaiya B, Cornforth MN, Ullrich RL. Radiation-Induced Chromosomal instability in BALB/c and C57BL/6 Mice: The difference is as clear as black and white. Radiat Res 1997; 147(2): 121-5.
52. Yu T, MacPhail SH, Banáth JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair 2006; 5(8): 935-46.
53. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. cH2AX and cancer. Nature Reviews Cancer 2008; 8(12): 957-67.
54. Menegakis A, Yaromina A, Eicheler W, Dö rfler AR, Beuthien- Baumann B, Thames HD, et al. Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by cH2AX staining. Int J Radiat Biol 2009; 85(11): 1032-41.
55. Ichijima Y, Sakasai R, Okita N, Asahina K, Mizutani S, Teraoka H. Phosphorylation of histone H2AX at M phase in human cells without DNA damage response. Biochem Biophys Res Commun 2005; 336(3): 807-12.
56. Firsanov D, Solovjeva L, Svetlova M. H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues. Clinical Epigenetics 2011; 2(2): 283-97.
57. Löbrich M, Shibata A, Beucher A, Fisher A, Esminger M, Goodarzi AA, et al. cH2AX foci analysis for monitoring DNA double-strand break repair: Strengths, limitations and optimization. Cell Cycle 2010; 9(4): 662-9.
58. MacPhail SH, Banáth JP, Yu Y, Chu E, Olive PL. Cell cycledependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not x-irradiated G1-phase cells. Radiat Res 2003; 159(6): 759-67.
59. Nowak E, Etienne O, Millet P, Lages CS, Mathieu C, Mouthon MA, et al. Radiation-induced H2AX phosphorylation and neural precursor apoptosis in the developing brain of mice. Radiat Res 2006; 165(2): 155-64.
60. Paris L, Cordelli E, Eleuteri P, Grollino MG, Pasquali E, Ranaldi R, et al. Kinetics of c-H2AX induction and removal in bone marrow and testicular cells of mice after X-ray irradiation. Mutagenesis 2011; 26(4): 563-72.
61. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nature Reviews Cancer 2009; 9(7): 501-7.
62. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer Therapy. Cancer 1994; 73(8): 2013-26.
63. Mitchel REJ, Jackson JS, Morrison DP, Carlisle SM. Low doses of radiation increase the latency of spontaneous lymphomas and spinal osteosarcomas in cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 2003; 159(3): 320-7.
64. Ina Y, Sakai K. Prolongation of life span associated with immunological modification by chronic low-dose-rate irradiation in MRL-lpr/lpr mice. Radiat Res 2004; 161(2): 168-73.
65. Ina Y, Tanooka H, Yamada T, Sakai K. Suppression of thymic lymphoma induction by life-long low-dose-rate irradiation accompanied by immune activation in C57BL/6 mice. Radiat Res 2005; 163(2): 153-8.
66. Phan N, De Lisio M, Parise G, Boreham DR. Biological effects and adaptive response from single and repeated computed tomography scans in reticulocytes and bone marrow of C57BL/6 mice. Radiat Res 2011; 177(2): 164-75.
67. Day TK, Zeng G, Hooker AM, Bhat M, Scott BR, Turner DR, et al. Extremely low priming doses of X radiation induce an adaptive response for chromosomal inversions in pKZ1 mouse prostate. Radiat Res 2006; 166(5): 757-66.
68. Day TK, Zeng G, Hooker AM, Bhat M, Scott BR, Turner DR, et al. Adaptive response for chromosomal inversions in pKZ1 mouse prostate induced by low doses of X radiation delivered after a high dose. Radiat Res. 2007; 167(6): 682-92.
69. Zeng G, Day TK, Hooker AM, Blyth BJ, Bhat M, Tilley WD, et al. Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutat Res 2006; 602(1-2): 65-73.
70. Mitchel RE, Jackson JS, Carlisle SM. Upper dose thresholds for radiation-induced adaptive response against cancer in high-doseexposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 2004; 162(1): 20-30.
71. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121(3): 200-6.
72. Zumbo BD, Hubley AM. A note on misconceptions concerning prospective and retrospective power. Journal of the Royal Statistical Society: Series D (The Statistician). 1998; 47(2): 385-8.
73. Raina K, Serkova NJ, Agarwal R. Silibinin Feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study. Cancer Res 2009: 3731-5.
74. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, et al. Blockade of fbetag-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 2007; 67(14): 6925-35.